newsfilter
← Latest News
Business Wire·

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Cholangitis (PBC)